Physician profile
Lissa Shaffer
NPI 1639856404
$2,263.41
in general payments reported to CMS, 2019-2025
26 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $117 · 2023: $542 · 2024: $1,092 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.29 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $753.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $215.08 | 2022-2024 | Tagrisso, Enhertu, Lynparza |
| Abbvie INC. | $213.92 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $155.11 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Sobi, INC | $130.23 | 2023-2024 | |
| Janssen Biotech, INC. | $93.15 | 2024 | Erleada, Akeega, Balversa |
| Incyte Corporation | $83.31 | 2024-2025 | Jakafi |
| Genmab U.S., INC. | $68.54 | 2023-2024 | Epkinly, Tivdak |
| Blueprint Medicines Corporation | $58.13 | 2024 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $52.53 | 2024 | |
| Exeltis, USA INC. | $50.77 | 2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $48.57 | 2024 | Alunbrig |
| Karyopharm Therapeutics INC. | $46.02 | 2024 | Xpovio |
| Seagen INC. | $31.83 | 2023 | Tukysa |
| Pfizer INC. | $30.42 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $29.44 | 2024 | |
| Tersera Therapeutics LLC | $27.85 | 2024 | Zoladex |
| Jazz Pharmaceuticals INC. | $27.55 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $24.35 | 2024 | Libtayo |
| Lilly USA, LLC | $24.08 | 2023 | Verzenio, Retevmo, Jaypirca |
| Celgene Corporation | $20.04 | 2023 | Reblozyl |
| Exelixis INC. | $18.87 | 2024 | Cabometyx |
| Coopersurgical, INC. | $16.62 | 2025 | Paragard T 380a |
| Gilead Sciences, INC. | $16.51 | 2023 | |
| Morphosys, US INC. | $13.77 | 2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $13.43 | 2023 | Opdualag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lissa Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.